1. Introduction {#sec1-ijerph-17-00356}
===============

The oral environment is a very complex microenvironment consisting of multiple bacteria and their associated biofilms which can start a series of immune inflammatory reactions leading to the destruction of the periodontium \[[@B1-ijerph-17-00356]\]. Multiple infections resulting from poor oral health could also evoke a systemic response \[[@B2-ijerph-17-00356]\]. Many studies have provided scientific evidence suggesting that periodontitis could affect an individual systemically, contributing to cardiovascular disease \[[@B3-ijerph-17-00356]\], diabetes \[[@B4-ijerph-17-00356]\], and respiratory disease \[[@B5-ijerph-17-00356]\].

Pneumonia is a common respiratory infectious disease of the pulmonary parenchyma caused by bacteria, mycoplasma, viruses, fungi, or parasites. Bacterial pneumonia is a common and significant cause of mortality and morbidity in human populations \[[@B6-ijerph-17-00356]\]. Pneumonia has been the third most common cause of death in Taiwan in 2018 \[[@B7-ijerph-17-00356]\]. Dental biofilms and periodontal inflammation appear to be risk factors for the development and/or progression of pneumonia \[[@B8-ijerph-17-00356]\]. In addition, studies have reported that respiratory pathogens preferentially colonize the teeth or dentures rather than soft tissue in the oral cavity \[[@B9-ijerph-17-00356],[@B10-ijerph-17-00356]\]. This indicates that dental biofilm acts as a reservoir for respiratory pathogens. Therefore, oral interventions aimed at reducing the bacteria count may result in a reduced incidence of pneumonia.

However, there is limited information on whether periodontal treatment could reduce pneumonia risk. We hypothesized that chronic periodontitis patients with periodontal treatment have a lower risk of developing pneumonia than the general population. In this study, we conducted a nationwide population-based study using the Taiwanese National Health Research Insurance database (NHIRD) to investigate the impact of periodontal treatment on pneumonia risk, with a cohort study design.

2. Materials and Methods {#sec2-ijerph-17-00356}
========================

2.1. Data Source {#sec2dot1-ijerph-17-00356}
----------------

The compulsory National Health Insurance program, which has operated since 1995, enrolled nearly the whole Taiwanese population in 2014 \[[@B11-ijerph-17-00356]\]. The Longitudinal Health Insurance Database 2010 (LHID2010), a part of the NHIRD, was used in this cohort study. LHID2010 comprises 1,000,000 randomly sampled beneficiaries enrolled from the National Health Insurance (NHI) program in 2010. Collected data such as registration information and dental and medical records on these individuals were described previously \[[@B12-ijerph-17-00356],[@B13-ijerph-17-00356],[@B14-ijerph-17-00356]\]. The NHIRD identifies diseases on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The accuracy and validity of NHIRD diagnosis codes have been documented. This study was approved by the Chung Shan Medical University Hospital institutional review board (CS2-15071). This study also complies with the guidelines of strengthening the reporting of observational studies in epidemiology (STROBE).

2.2. Study Sample {#sec2dot2-ijerph-17-00356}
-----------------

The data for this cohort study were retrieved from LHID2010. All patients aged ≥20 years with chronic periodontitis diagnosed by ICD-9-CM code 523.4 were identified. The periodontal treatment group comprised individuals who had received periodontal treatment within 1 year following their diagnosis of chronic periodontitis. To validate the periodontal treatment sourced from LHID2010, we identified periodontal treatment cases by NHI system treatment codes (scaling 91003, 91004; subgingival curettage/root planning 91006, 91007, 91008; periodontal flap surgery 91009, 91010). Only patients with at least three outpatient service claims were included. Patients diagnosed with chronic periodontitis before 2001 were also excluded. The newly diagnosed chronic periodontitis patients with periodontal treatment from 2001 to 2012 were used as the periodontal treatment cohort. The index date was defined as the first time of treatment in the 1 year following the patient's diagnosis of chronic periodontitis. A comparison cohort was randomly selected from those participants who were never diagnosed with any type of gingival and periodontal diseases between 2000 and 2013 (ICD-9-CM: 523) in order to ensure the accuracy of the periodontal health information.

2.3. Covariates and Matching {#sec2dot3-ijerph-17-00356}
----------------------------

The baseline variables included age, gender, monthly income, urbanization, and comorbidities. The monthly income data used a NT \$20,000 interval to distinguish income levels according to the basic wage (NT \$19,047) announced by the Ministry of Labor in 2013 \[[@B15-ijerph-17-00356]\]. Therefore, monthly income was categorized as follows: \<NT \$20,000, NT \$20,000 to NT \$40,000, and \>NT \$40,000. The degree of urbanization was clustered into urban, suburban, and rural based on population density, the population ratio of people with college-or-above educational levels, the population ratio of elderly people over 65 years old, the population ratio of agriculture workers, and the number of physicians per 100,000 people \[[@B16-ijerph-17-00356]\]. The comorbidities included hypertension (ICD-9-CM: 401--405), hyperlipidemia (ICD-9-CM: 272.0--272.4), diabetes (ICD-9-CM: 250), chronic obstructive pulmonary disease (ICD-9-CM: 490--496), chronic kidney disease (ICD-9-CM: 585), and stroke (ICD-9-CM: 430--438). Those comorbidities were defined before the index date within one year.

The comparison cohort was then frequency-matched according to age and gender at a 1:2 ratio in order to provide the same index date for both groups. During matching, we excluded patients who received a diagnosis of pneumonia before the index date. Moreover, propensity score matching (1:1) was performed for the comparison group according to age, gender, monthly income, urbanization, hypertension, hyperlipidemia, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, and stroke. The propensity score was a probability that was calculated from logistic regression. By matching the propensity score, the difference in disease severity between the two groups could be reduced. The flow chart of case selection and exclusion is shown in [Figure 1](#ijerph-17-00356-f001){ref-type="fig"}.

2.4. Pneumonia Event {#sec2dot4-ijerph-17-00356}
--------------------

The outcome was defined as newly diagnosed pneumonia (ICD-9-CM: 481, 482, 483, 485, and 486) from emergencies or hospitalization to confirm the accuracy of diagnosis. All patients were traced until the occurrence of pneumonia, withdrawal from the social insurance system, or the end of 2013, whichever came first.

2.5. Statistical Analysis {#sec2dot5-ijerph-17-00356}
-------------------------

The Student's t-test and Chi-square test were used to compare the demographic and clinical characteristics of patients with periodontal treatment with those of the comparison groups. The Kaplan--Meier analysis was used to plot the cumulative incidence of pneumonia. The log-rank test was used to compare differences between these two cohorts. The Cox proportional hazard models were applied to estimate the hazard ratios and 95% confidence intervals of periodontal treatment. All statistical analyses were performed using SPSS version 18 (SPSS, IBM, Chicago, IL, USA). The level of statistical significance was set at *p* \< 0.05.

3. Results {#sec3-ijerph-17-00356}
==========

The baseline demographic data of this study are listed in [Table 1](#ijerph-17-00356-t001){ref-type="table"}. In total, 49,400 patients with periodontal treatment and 49,400 people in the comparison group with similar age, income, and urbanization distributions were selected in this study (*p* \> 0.05). There were no significant potential differences in comorbidities between the periodontal treatment group and the comparison group (*p* \> 0.05).

A total of 1922 and 2504 patients were newly diagnosed with pneumonia in the periodontal treatment cohort and comparison cohort, respectively. The incidence density rate of pneumonia in the periodontal treatment group was only 5.1 per 1000 person-years ([Table 2](#ijerph-17-00356-t002){ref-type="table"}). The incidence density rate was about 0.75-fold lower in the periodontal treatment group than in the comparison group (6.8 per 1000 person-years). Patients with periodontal treatment had a lower risk of pneumonia as compared with the comparison group (adjusted HR: 0.69; 95%CI: 0.65--0.73). The age-specific adjusted HR of pneumonia increased with age from 2.28 (age 40--64 years) to 7.98 (age ≥ 65 years) as compared with the age 20--39 group. The male group had a higher pneumonia risk than the female group (adjusted HR: 1.60; 95%CI: 1.51--1.71). The higher monthly income group had a lower risk for pneumonia (adjusted HR: 0.65; 95%CI: 0.58--0.73). Those living in rural areas had a higher risk of pneumonia (adjusted HR: 1.18; 95%CI: 1.07--1.31). In addition, patients with hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, and stroke demonstrated a significant risk of pneumonia (*p* \< 0.05).

As shown in [Figure 2](#ijerph-17-00356-f002){ref-type="fig"}, patients who received periodontal treatment had a significantly lower cumulative incidence of pneumonia than subjects in the comparison group over the 12 year follow-up period (using the log-rank test, *p* \< 0.001).

As shown in [Table 3](#ijerph-17-00356-t003){ref-type="table"}, the mean follow-up duration in the periodontal treatment and comparison cohorts was 7.66 years and 7.41 years, respectively. The mean interquartile range for pneumonia was 5.34 and 5.16 years for the periodontal treatment cohort and the comparison cohort, respectively.

Further stratification with respect to the type of periodontal treatment, shown in [Table 4](#ijerph-17-00356-t004){ref-type="table"}, indicated that scaling could significantly reduce the risk of pneumonia (adjusted HR: 0.70; 95% CI: 0.66--0.75) compared to lack of periodontal treatment. In addition, intensive periodontal treatment such as flap surgery could lower pneumonia risk about 66% compared with lack of periodontal treatment (adjusted HR: 0.34; 95%CI: 0.19--0.62).

4. Discussion {#sec4-ijerph-17-00356}
=============

Although several studies have reported the association of periodontal disease and pneumonia \[[@B17-ijerph-17-00356],[@B18-ijerph-17-00356],[@B19-ijerph-17-00356]\], little is known about the relationship between periodontal treatment and pneumonia risk. To the best of our knowledge, this is the first nationwide population-based cohort study reporting that the risk of pneumonia in patients who received periodontal treatment was lower than in the untreated group. Similar results were found by Yoneyama et al. who reported that intervention promoting oral hygiene could reduce pneumonia in elder inpatients and patients in nursing homes \[[@B20-ijerph-17-00356]\]. Recently, intensive periodontal treatment was associated with a 29% reduction in the risk of hospitalization for pneumonia in hemodialysis patients \[[@B21-ijerph-17-00356]\]. These data demonstrate that dental prophylaxis is very important for the reduction of pneumonia.

The oral cavity is an important source of bacteria that cause infections of the respiratory system. The connection of periodontal diseases and pneumonia might result from the colonization of pathogenic bacteria present in dental biofilm \[[@B22-ijerph-17-00356]\], followed by aspiration of the colonized pathogens, which is considered a significant risk factor for pneumonia \[[@B23-ijerph-17-00356],[@B24-ijerph-17-00356]\]. Various respiratory pathogens such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Enterobacter cloacae* were found in the dental biofilm of susceptible individuals \[[@B25-ijerph-17-00356],[@B26-ijerph-17-00356],[@B27-ijerph-17-00356]\]. In addition, many periodontal bacteria species have been cultured from infected lung fluids such as *Porphyromonas gingivalis*, *Eikenella corrodens*, *Fusobacterium nucleutum,* and *Actinomyces* \[[@B28-ijerph-17-00356],[@B29-ijerph-17-00356]\]. These findings are a direct evidence of the positive association between periodontal disease and pneumonia. Therefore, dental biofilm could serve as an important reservoir of respiratory pathogens.

The monthly income and urbanization of the locations of NHI registration were used as a proxy parameter for socioeconomic status. It is not surprising that our results found that higher income and level of urbanization were associated with a relatively lower risk of pneumonia. This might be due to the larger availability of dental service and favorable patients' attitudes toward periodontal treatment in those areas. These factors would influence people's utilization of the NHI in Taiwan. However, further assessments such as through questionnaires and surveys are required.

Poor oral hygiene in dentate patients was found to cause significantly higher salivary bacterial counts than in individuals with good oral hygiene \[[@B30-ijerph-17-00356]\]. Poor oral hygiene could increase the complexity and mass of the dental biofilm, enhancing further interactions between oral and respiratory pathogens \[[@B31-ijerph-17-00356]\]. In clinical dentistry, scaling, root planing, and flap surgery with oral hygiene instruction are the guidelines for regular periodontal treatment. These procedures can effectively remove dental biofilm and calculus from teeth surfaces and reduce inflammatory conditions, improving periodontal health. This may explain why periodontal treatment could reduce the risk of pneumonia in this study. Moreover, intensive periodontal treatment such as root planing and flap surgery were revealed to be more powerful in lowering the pneumonia risk than dental prophylaxis by scaling.

The strengths of this study are the use of a large, longitudinal sample size to evaluate the pneumonia risk in the periodontal treatment and comparison groups. The cohort study design used could confer a higher level of evidence to demonstrate a causal relationship between periodontal treatment and the decrease of the risk of pneumonia.

However, some potential limitations of this observational study should be addressed. First, this study was not a prospective, randomized study of chronic periodontitis patients who did or did not receive adequate periodontal treatment. Future study with controlled interventions is required. Second, we are uncertain about the periodontal health status of the comparison cohort due to this being a register-based study. Only individuals sought for dental prophylaxis and periodontal treatment could be recruited in the NHI system. Therefore, the exclusion of patients with any gingival and periodontal disease from 2000 to 2013 in the comparison group could reduce the selection bias and avoid the confounding variates. This is the reason why we chose individuals without periodontal diseases diagnoses (ICD-9-CM code 523) as the comparison cohort. Thirdly, the contributions of smoking habits, alcohol use, family history, or nutrition status factors could not be investigated using LHID2010. Fourthly, all of the diagnoses used ICD-9-CM codes in the NHIRD. Ventilator-associated pneumonia is a major infection in hospitals. The severity, pathogens, or causes of pneumonia were not reported in this database. Fifthly, the definitive code of aspiration pneumonia was included in ICD-9; however, aspiration pneumonia is a dynamic disease, and we could not distinguish between aspiration pneumonia and infectious pneumonia from the claims-based insurance database. These may compromise our findings and result in an inadequate adjustment of confounding factors. Finally, in this study, the majority of the participants were Taiwanese. It still remains uncertain whether the findings could be generalized to other ethnic groups.

5. Conclusions {#sec5-ijerph-17-00356}
==============

In conclusion, this nationwide cohort study suggests that patient with periodontal treatment is associated with a decreased risk for pneumonia. Dentists and medical doctors should be more aware of the correlation of periodontal diseases and pneumonia. These findings could provide evidence to policy-makers that periodontal treatment is a potential modifiable factor in the primary prevention of pneumonia.
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###### 

Demographic data of matched study cohorts.

                                          Periodontal Treatment Group (N = 49,400)   Comparison Group (N = 49,400)                    
  --------------------------------------- ------------------------------------------ ------------------------------- --------- ------ -------
  Age                                                                                                                \<0.001          
  20--39                                  20,500                                     41.5                            21,279    43.1   
  40--64                                  23,838                                     48.3                            23,295    47.2   
  ≥65                                     5062                                       10.2                            4826      9.8    
  Mean ± SD                               44.25 ± 14.82                              44.15 ± 14.5                    0.283            
  Gender                                                                                                                              0.049
  Female                                  26,242                                     53.1                            26,551    53.7   
  Male                                    23,158                                     46.9                            22,849    46.3   
  Monthly income                                                                                                                      0.007
  \<NT \$20,000                           24,560                                     49.7                            25,021    50.6   
  NT \$20,000--NT \$40,000                17,660                                     35.7                            17,444    35.3   
  \>NT \$40,000                           7180                                       14.5                            6935      14.0   
  Urbanization                                                                                                                        0.797
  Urban                                   31,674                                     64.1                            31,750    64.3   
  Suburban                                14,381                                     29.1                            14,352    29.1   
  Rural                                   3345                                       6.8                             3298      6.7    
  Hypertension                            5761                                       11.7                            5505      11.1   0.010
  Hyperlipidemia                          1997                                       4.0                             1973      4.0    0.697
  Diabetes                                2651                                       5.4                             2527      5.1    0.077
  Chronic obstructive pulmonary disease   1367                                       2.8                             1326      2.7    0.423
  Chronic kidney disease                  214                                        0.4                             233       0.5    0.368
  Stroke                                  887                                        1.8                             872       1.8    0.718

The Student's t-test and Chi-squared test were used to test the difference of continuous and categorical variables, respectively.
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###### 

Risk factor analysis of pneumonia development.

                                          No. of Event   Observed Person-Years   ID     Crude HR   95% CI         Adjusted HR ^†^   95% CI
  --------------------------------------- -------------- ----------------------- ------ ---------- -------------- ----------------- ------------
  Group                                                                                                                             
  Comparison                              2,504          366,251                 6.8    1                         1                 
  Periodontal treatment                   1922           378,522                 5.1    0.74       0.70--0.78     0.69              0.65--0.73
  Age                                                                                                                               
  20--39                                  703            325,108                 2.2    1                         1                 
  40--64                                  1889           351,970                 5.4    2.51       2.30--2.73     2.28              2.09--2.50
  ≥65                                     1834           67,695                  27.1   12.95      11.87--14.13   7.98              7.24--8.79
  Gender                                                                                                                            
  Female                                  1800           400,036                 4.5    1                         1                 
  Male                                    2626           344,737                 7.6    1.70       1.60--1.80     1.60              1.51--1.71
  Monthly income                                                                                                                    
  \<NT \$20,000                           2508           373,501                 6.7    1                         1                 
  NT \$20,000--NT \$40,000                1558           262,588                 5.9    0.89       0.83--0.94     0.91              0.85--0.97
  \>NT \$40,000                           360            108,685                 3.3    0.49       0.44--0.55     0.65              0.58--0.73
  Urbanization                                                                                                                      
  Urban                                   2589           478,277                 5.4    1                         1                 
  Suburban                                1390           216,786                 6.4    1.18       1.11--1.26     1.05              0.98--1.12
  Rural                                   447            49,710                  9.0    1.66       1.50--1.84     1.18              1.07--1.31
  Hypertension                            1403           76,450                  18.4   4.18       3.93--4.46     1.42              1.31--1.53
  Hyperlipidemia                          360            25,386                  14.2   2.63       2.36--2.92     0.95              0.85--1.07
  Diabetes                                729            34,065                  21.4   4.27       3.94--4.62     1.78              1.63--1.94
  Chronic obstructive pulmonary disease   431            19,815                  21.8   3.95       3.57--4.36     1.77              1.6--1.96
  Chronic kidney disease                  103            2577                    40.0   7.25       5.96--8.82     2.69              2.21--3.28
  Stroke                                  361            11,462                  31.5   5.88       5.28--6.55     1.74              1.55--1.95

Bold font represents statistical significance (*p* \< 0.05). ID: Incidence density, per 1000 person-years. † Adjusted for age, gender, monthly income, urbanization, hypertension, hyperlipidemia, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, and stroke.
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###### 

Track time of the periodontal treatment and comparison cohorts.

  ------------------------------------------------------------------------------------------------
                                    Periodontal Treatment Group\   Comparison Group\   *p*-Value
                                    (N = 49,400)                   (N = 49,400)        
  --------------------------------- ------------------------------ ------------------- -----------
  Follow-up duration (years)        7.66 ± 3.05                    7.41 ± 3.14         \<0.001

  Time to event (years), N = 4426   5.34 ± 3.07                    5.16 ± 3.01         0.057
  ------------------------------------------------------------------------------------------------

The Student's t-test was used to test the difference between continuous variables.
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###### 

Hazard ratios of pneumonia development among different periodontal treatments.

                          N        No. of Event   Crude HR   95% CI       Adjusted HR ^†^   95% CI
  ----------------------- -------- -------------- ---------- ------------ ----------------- ------------
  Periodontal treatment                                                                     
  None                    49,400   2504           1                       1                 
  Scaling                 44,253   1783           0.74       0.7--0.79    0.70              0.66--0.75
  Root planing            4380     128            0.76       0.64--0.91   0.58              0.48--0.69
  Flap surgery            767      11             0.35       0.19--0.63   0.34              0.19--0.62

† Adjusted for age, gender, monthly income, urbanization, hypertension, hyperlipidemia, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, and stroke.
